Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gedeon Richter Tipped For M&A As Cash Pile Rises

‘Multiples Have Reduced And Stock Prices Fallen,’ Company Acknowledges

Executive Summary

Gedeon Richter is keeping a keen eye on further business development opportunities, including M&A. The company is also continuing to tackle the impact of Russia’s invasion of Ukraine, observing that “there’s still not very much clarity on how the situation will evolve.”

You may also be interested in...



Krka Keeps Focus On Russia-Ukraine As Sales Climb 9%

Slovenia’s Krka surprised the market with nearly 10% group turnover growth in the first quarter, driven by increases in all six of its sales regions, “most key markets, and by all product and service groups.”

Deal Watch: AbbVie Partners With Gedeon Richter In Neuropsychiatry

Seeing strong sales with legacy Allergan’s Vraylar, AbbVie teams with Gedeon Richter on novel dopamine receptor modulators. AB Studio, CR Biopharma partner on COVID-19 neutralizing antibody.

Gedeon Richter Pledges New Markets For Teriparatide Biosimilar

Gedeon Richter aims to continue the global roll-out of its teriparatide biosimilar, having enjoyed continued solid growth for the Forsteo rival during the first quarter.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151895

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel